论文部分内容阅读
目的 检测DNA拓扑异构酶Ⅱα(TOPOⅡα)、p53在乳腺癌组织的表达 ,并探讨其与化疗耐药的关系。方法 采用免疫组化S P法检测 91例未经抗肿瘤治疗的原发乳腺癌和 1 8例术后经化疗复治的乳腺癌组织中TOPOⅡα、p53蛋白的表达。结果 TOPOⅡα在原发乳腺癌中阳性率为42 % ,阳性率与肿瘤类型、组织学分级、肿瘤大小、临床分期有关 (P <0 0 5 ,其中组织分级P <0 0 1 ) ;术后经化疗复治乳腺癌中阳性率为 1 7% ,与原发癌相比显著降低 (P <0 0 5) ;突变型p53在原发乳腺癌与化疗复治乳腺癌阳性率差异无显著性 (P >0 0 5) ;p53蛋白表达与TOPOⅡα无相关性 (P >0 0 5)。结论 TOPOⅡα表达可作为反映肿瘤增殖和恶性度的指标。TOPOⅡα参与化疗耐药性形成。免疫组化检测TOPOⅡα表达对于是否选TOPOⅡ抑制剂化疗有一定参考价值
Objective To detect the expression of DNA topoisomerase IIα (TOPOIIα) and p53 in breast cancer tissues and to explore their relationship with chemotherapy resistance. Methods Immunohistochemical SP method was used to detect the expression of TOPOIIα and p53 protein in 91 cases of primary breast cancer without antitumor therapy and 18 cases of breast cancer tissues treated with chemotherapy. Results The positive rate of TOPOIIα in primary breast cancer was 42%. The positive rate was related to tumor type, histological grade, tumor size, and clinical stage (P < 0.05, of which the histological grade was P <0 01); The positive rate of chemotherapy for retreatment of breast cancer was 1 7%, which was significantly lower than that of primary cancer (P < 0.05). There was no significant difference in the positive rate of p53 between primary breast cancer and chemotherapy retreatment. P >0 0 5); p53 protein expression had no correlation with TOPOIIα (P > 0 05). Conclusion TOPOIIα expression can be used as an indicator of tumor proliferation and malignancy. TOPOIIα is involved in the formation of chemotherapy resistance. Immunohistochemical detection of TOPOIIα has certain reference value for the selection of TOPO II inhibitor chemotherapy